cyrilzakka/clinical-trials huggingface dataset:
REBT Intervention Program for Career Decision-making Difficulties in High School Pupils

Career decision-making difficulties are frequent problems for adolescents. Regular intervention or prevention programs mainly provide information for the students about themselves, about the world of work, about their interests and preferences etc. Rational emotive behavioral therapy (REBT), a form of Cognitive behavioral therapy (CBT) provides help for adolescents to efficiently cope with emotional problems (e.g., psychological distress) related to the career decision-making process. The present study aims to investigate the efficiency of an REBT career intervention program implemented in a school setting. School settings are appropriate to deliver group intervention for students. Classes from Romanian public high-schools will be randomized in either intervention or treatment as usual groups.

The intervention will be group based, delivered in 8 sessions, over 8 weeks. Each of the eight modules aimed a different component: Psychoeducation, Information about self and world of work, Steps of career decision-making, Problem solving. Additionally, for the REBT groups: Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/behavioral activation and emotional problem solving, Maintenance of gaining. Homework would be given at every session. REBT intervention programs delivered in school settings represent ecological modalities to target vulnerable groups. Adolescents will complete assessments at four time points: T1 (baseline), T2 (post-intervention), T3 (3 months follow-up) and T4 (6 months follow-up).

Eligibility Criteria:
Inclusion Criteria:

* Adolescents will have ages 16 years to 19 years (11th grade at high school).
* Are attending high school.
* Parents will sign the informed consent and adolescents provide informed assent.

Exclusion Criteria:

* Age below 16 or above 19 years.
* No signed informed consent from the parents.
* Uninterpretable answers on the validation items of the CDDQ (items nr. 7 and 12)
Screening Mammography and Latinas: A Multilevel Intervention

¡Fortaleza Latina! is a multi-level randomized trial to increase participation in mammography screening among Latinas who seek care at a community health center in Western Washington.

In partnership with the partnering community health center, we have obtained lists of women patients aged 42 to 74 years old who had not had a mammogram in the last two years and resided within defined radii of the four clinics. Baseline and one year follow-up surveys will be obtained by in person home interview. Participants are randomized within clinic to intervention or comparison group. The intervention consist of two motivational interviewing sessions, one in person in the home, and one telephone follow-up. The study hypothesis is that a higher proportion of participants in the motivational interviewing arm will obtain a screening mammogram within the study period than those in the comparison arm.

Breast cancer is the most common cancer among Hispanic women in the United States (US) and five-year survival from breast cancer is lower in Hispanic than in non-Hispanic White women. This reduced survival has a number of potential causes, but differential screening rates may be a partial explanation, since Hispanic women have lower breast cancer screening rates than non-Hispanic White women. The overall purpose of the study is to develop and evaluate a culturally-appropriate intervention aimed at increasing screening mammography rates in a clinic-based sample of predominantly Mexican American women in Western Washington.

The recruitment goal of the Fortaleza Latina study is approximately 500 Latina women aged 40-74 who have had a clinic visit within the past 5 years, but no recent mammogram, from the four selected Community Health Center clinics. After providing informed consent and completing a baseline assessment, eligible women are randomly assigned to intervention or comparison group, within clinic. The individual-level intervention implements motivational interviewing (MI) in two participant encounters. MI is a direct counseling style, led by a promotora (lay health advisor), that elicits behavior change by helping participants explore and resolve ambivalence.

Of the 2194 women contacted by field interviewers, a total of 710 surveys have been completed; of these, 542 were eligible and have been randomized and enrolled into the Fortaleza Latina study (279 intervention, 263 usual care).

Eligibility Criteria:
Inclusion Criteria:

* Hispanic/Latina ethnicity
* Have been seen in one of the 4 community clinics in the past 5 years
* have NOT had a mammogram within the past two years
* Residing within 20 miles of one of the participating clinics

Exclusion Criteria:

* Participants who do not match the Eligibility Criteria listed above
* Medical record verified recent mammogram
Correlation of the Neck Disability Index (NDI) and Voice Handicap Index (VHI) in Neck Pain Patients and Patients With Voice Disorders

This study investigates in patients whose primary complaint is either neck pain and/or a voice disorder , if there are any correlations between subjective neck and voice symptoms according to Neck Disability Index (NDI) and Voice Handicap Index (VHI). NDI and VHI questionnaire results for voice disordered patients will be retrieved from the data base of the Department of Phoniatrics and Speech Pathology, University Hospital Zurich. Neck pain patient questionnaire data will be retrieved from an ongoing study. The agreement between subjective neck handicap (NDI) and voice handicap (VHI) will be statistically analysed.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old
* primary diagnose of a functional disorder of the muscular structure in the neck area
* primary diagnose of a functional or secondary structural voice disorder

Exclusion Criteria:

* systemic illness of the motion apparatus (i.e., polyarthritis rheumatica)
* acute cancer
* neurogenic voice and swallow disorder
* Intubation within the last 18 months
* lack of german knowledge, (not able to fill out a questionnaire independently)
Imaging of Cognition, Learning, and Memory in Aging

This investigation is designed to study how the brain functions when it is performing explicit memory tasks, and furthermore how the brain systems supporting performance on these tests change as a function of aging. Implicit memory tasks may be distinguished from explicit memory tests in that explicit memory characterizes the directed or intentional recollection of previously learned information or events. In contrast, implicit (or nonconscious) memory is expressed in the facilitation of performance on some task or judgment on a stimulus owing to a prior presentation of that stimulus, without any necessary conscious awareness of the prior presentation. The investigators propose to use functional Magnetic resonance Imaging (fMRI) to measure brain activity during the performance of carefully designed explicit memory tasks. Comparison of brain activity during the different test conditions will provide information about the brain areas that are involved in mediating specific aspects of performance. Both older and younger individuals will be tested in order to understand age related changes in the brain activity. In order to examine the interactions between participants' differential levels of amyloid burden and their performance on cognitive tasks and fMRI neural activation, the investigators also propose PET imaging of older participants.

The basic approach to measuring the brain activity associated with a given cognitive process (or processes) is as follows: It is known that increases in brain neuronal activity are associated with local increases in energy metabolism. Under normal circumstances, increases in brain metabolism lead to local changes in blood oxygenation in venules and larger veins. This change in blood oxygenation can be detected imaging methods which are sensitive to the differences in magnetic state between oxygenated and deoxygenated hemoglobin.

The ultimate benefit of this research is to better understand how changes in both performance and the brain organization underlying that performance are affected by aging.

Eligibility Criteria:
Inclusion Criteria:

* Aged 20-30 or 60-70
* Residing near Columbia University Medical Center
* Must be willing and able to participate

Exclusion Criteria:

* Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
* Pregnancy
* Lactating Women
* Current, past, or anticipated exposure to radiation
* Significant active physical illness
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory patients with CD19+ B cell lymphoma.

This is a study for the patients with B cell lymphoma. Maximum tolerated dose climbing test is expected into the group of 9 cases of patients. And Phase II expected into the group of 11 subjects, selected the above safe dose, carrying out a research into the clinical effectiveness. Subjects will be collected their T cells and modify them, the modification is a genetic change, that CD19:4-1BB:CD28:CD3 modified T cells, in order to tells the T cells to recognize their target tumor cells and potentially kill them, but not other normal cells in the subject's body. The CART cells will then be expanded in vitro and then administered to subjects. The purpose of this study is observe the MTD and to assess the safety and feasibility of CART cells in the patients with relapsed and refractory CD19+ B cell lymphoma.

Eligibility Criteria:
Inclusion Criteria:

* 1. 18 years to 70 years, expected survival \> 3 months;
* 2. CD19 positive B-cell lymphoma;
* 3. KPS \>80;
* 4. Having at least one measurable lesions;
* 5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN; bone marrow: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥ 80×109/L）;
* 6. No serious allergic constitution;
* 7. No other serous diseases that conflicts with the clinical program;
* 8. No other cancer history;
* 9. No serious mental disorder;
* 10. Informed consent is signed by a subject or his lineal relation.

Exclusion Criteria:

* 1. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test);
* 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
* 3. Active hepatitis B or hepatitis C infection;
* 4. Recent or current use of glucocorticoid or other immunosuppressor;
* 5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
* 6. Transaminase \>2.5ULN, Bilirubin \>3ULN，Creatinine\>1.25ULN
* 7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;
* 8. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results;
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.


Eligibility Criteria:
Inclusion Criteria:

* Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
* Subject is 18 years of age or older.
* Subject must be receiving hemodialysis 3 times weekly for at least 3 months
* Subject agrees to not participate in another study of an investigational agent during the study.
* Other Inclusion Criteria may apply

Exclusion Criteria:

* Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.
* Other investigational procedures while participating in this study are excluded.
* Anticipated or scheduled parathyroidectomy during the study period.
* Subject has received a parathyroidectomy within 3 months prior to dosing.
* Anticipated or scheduled kidney transplant during the study period.
* Subject has known sensitivity to any of the products or components to be administered during dosing.
* Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169).
* Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study).
* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
* Other Exclusion Criteria may apply
QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.


Eligibility Criteria:
Inclusion Criteria:

* Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs
* Patients who signed informed consent form

Exclusion Criteria:

* Age lower than 18
Standing Computed Tomography (SCT) Imaging of the Knee Joint

This study will help us decide the best way to image the knee for diagnostic purposes: Knee computed tomography vs knee x-ray. The computed tomography will provide a weight bearing 3D view.

This will be an ancillary study to the Multicenter Osteoarthritis Study (MOST) second renewal #201511711). Using a prototype Curve Beam Standing Computed Tomography (SCT) scanner to get a 3 dimensional picture of the knee joint, bilaterally. This scanner by Curve Beam 175 Titus Ave, Suite 300, Warrington, Pennsylvania 18976, has been approved by the Food and Drug Administration (FDA) for ankles and feet. This has been modified to do the scan of the knee but is not yet approved by the FDA for the knees. The proposed ancillary study would add the key benefit of providing more sensitive and accurate identification of prevalent knee osteoarthritis (OA) at baseline and incident knee OA at follow-up than is available with plain radiographs. In addition, it would enable biomechanical modeling of the knee joint on a larger scale than achieved in any prior study, allowing testing of biomechanical hypotheses regarding mechanisms of disease development and progression that have not been possible on this scale previously.

Eligibility Criteria:
Inclusion Criteria:

Only participants in the Multicenter Osteoarthritis Study (MOST) who attend a 0/144-month visit at the Iowa site are eligible for inclusion.

Additional Inclusion Criteria Include:

* Completed knee radiograph (posteroanterior view) at 0/144-month visit of primary MOST-second renewal study at the Iowa Site

Exclusion Criteria:

* Bilateral Total Knee Arthroplasty
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis

Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described.

The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.


Eligibility Criteria:
Inclusion Criteria:

* All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life

Exclusion Criteria:

* None
Decreasing Antibiotic Prescribing in Acute Respiratory Infections Through Nurse Driven Clinical Decision Support

This study evaluates the effects of a novel integrated clinical prediction tool on antibiotic prescription patterns of nurses for acute respiratory infections (ARIs). The intervention is an EHR-integrated risk calculator and order set to help guide appropriate, evidence-based antibiotic prescriptions for patients presenting with ARI symptoms.

The proposed project will fill a critical gap in the evidence base and answer the important question: can pivoting ARI CDS tools towards nurses overcome established implementation barriers to reducing antibiotic use? The proposal is highly innovative in three ways: It uses CDS tools to embed evidence-based risk stratification to enable nurse-led ARI management. It creates a nurse training program to support this nurse-led ARI treatment pathway. It will be evaluated and optimized using evidence-based implementation frameworks that will guide assessment of the fidelity, acceptability, adoption, cost, and sustainability of the tool. This will provide comprehensive implementation measures, formative and summative, and enable a rigorous understanding of barriers and facilitators to implementing nurse-led CDS tools for reducing antibiotic overprescribing. This study will provide much needed guidance on how to implement CDS-enabled, nurse-led ARI assessment and treatment to reduce antibiotic overprescribing.

Eligibility Criteria:
Inclusion Criteria:

Clinics:

* must be primary care and/or urgent care clinics
* should have a minimum of one registered nurse (RN) full time equivalents (FTE)

Nurses :

* be licensed to see patients and prescribed and/or recommend prescriptions for patients
* work a minimum of 0.5 FTE to ensure that they are seeing sufficient numbers of patients to maintain competency
* have access to the clinic EHR system, and use regularly as part of patient care

Patients:

* patients must have been seen at a participating clinic with a complaint of cough or sore throat.
* Ages 3-70 will be included for sore throat and ages 18-70 for cough

Exclusion Criteria:

* are unable or unwilling to provide informed consent
* are unable to participate meaningfully in an intervention that involves self-monitoring using software available in English (e.g., due to uncorrected sight impairment, illiterate, non-English-speaking, dementia)
* clinics will be excluded if phone call triage of patients with sore throat and cough is not performed by RNs
* Nurses will be excluded if they do not work with the clinic EHR as part of their workflow
* Patients with a history of chronic lung disease or immunosuppression will be excluded since the CPRs were not validated in these groups
Promoting Parental Skills and Enhancing Attachment in Early Childhood

Child psychological/behavioural disorders such as withdrawal may persist when the psychosocial context is unfavourable. Health promotion strategies (Olds' paradigm) have proved their efficacy in vulnerable populations. CAPEDP project sets out to evaluate a program of home visits in France

This program aims at reducing psychosocial disorders and promoting mental health, social support and attachment amongst at-risk young women and their family. 440 primigravida (pregnant women) will be randomised into two groups. The first group will receive routine follow-up as currently provided by national community health and social services. The second group will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.

Eligibility Criteria:
Inclusion Criteria:

* Being less than 26 years old
* Being pregnant for less than 27 weeks
* Being primiparous
* Living in the study area
* Being socially vulnerable: less than 12 years of education AND/OR socially isolated AND/OR eligible for a public health insurance for people with low resources.

Exclusion Criteria:

* Refusal to participate
* Not able to speak French
* Having a medical follow-up which necessitates regular contact with health professional
* Not having health insurance
* Persons for whom follow up at 27 months is impossible (evaluation at baseline)
Cardiovascular Effects of Exercise-related Hypoglycaemia in Patients With Type 1 Diabetes (Hypo Heart Exercise)

Patients with type 1 diabetes are recommended to perform at least 150 minutes of accumulated physical activity each week, however fear of hypoglycaemia is a well-known barrier to exercise in these patients. Previous experimental studies have almost exclusively focused on investigating cardiovascular effects of hypoglycaemia under resting conditions, however other underlying circumstances prior to or during a hypoglycaemic event, (e.g. exercise) are rarely discussed in the literature but might, nevertheless, be of significant clinical importance.

In this study, the investigators aim to investigate the QT interval dynamics and prothrombotic factors during exercise-related hypoglycaemia in comparison with hypoglycaemia under resting conditions, in patients with type 1 diabetes.

Fifteen patients with type 1 diabetes will be recruited for a crossover study including two test days, a combined euglycaemic- hypoglycaemic clamp combined with an exercise session and an euglycaemic- hypoglycaemic clamp during bed rest, respectively. Furthermore, the participants will be schedueled for a 24-hours followup visit after each test day for the purpose of investigating prolonged prothrombotic effects of hypoglycaemia. Patients will be randomised 1:1 to start with the combined exercise-clamp or the resting-clamp. The two test days will be separated by at least 4 weeks to minimise carry-over effects. A group of fifteen healthy individuals with normal glucose tolerance matched for age, gender and body mass index, will be recruited for a single blood test aiming to compare baseline coagulation status with patients with type 1 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Informed and written consent
* Type 1 diabetes diagnosed according to the criteria of the World Health Organization (WHO)
* Age ≥ 18 years
* Insulin treatment for ≥1 year

Exclusion Criteria:

* Arrhythmia diagnosed prior to the screening visit.
* Ischaemic heart disease or myocardial infarction diagnosed prior to the screening visit.
* Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion
* Heart failure (left ventricular ejection fraction \<45%) diagnosed prior to the screening visit.
* Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
* ECG with left or right bundle branch block diagnosed prior to the screening visit.
* Thyroid dysfunction (except for well-regulated levothyroxine-substituted myxoedema)
* Anaemia (male: haemoglobin \<8.0; female: haemoglobin \<7.0 mmol/l)
* Treatment with anticoagulant or antiplatelet treatment.
* Bleeding disorder diagnosed prior to the screening visit.

Withdrawal criteria

- The participants may withdraw at will at any time